TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07448623: An Open-label Study to Evaluate the Biodistribution of 89Zr-coramitug and Investigate the Effects of Coramitug on Depleting TTR Amyloid Deposits in Myocardial Tissues Using PET/CT Imaging in Participants With ATTR-CM

Sponsor: Novo Nordisk A/S · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$2,076,992

Rescue Site Savings

+$1,377,136

Unlock Full NCT07448623 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07448623 Rescue Dossier →